Despite the availability of efficacious anti-obesity drugs (AOD), very few doctors are prescribing them to the patients. To assess the anti-obesity drug (AOD) prescription pattern in obese patients. Ninety four obese patients were studied at Department of Medicine and Department of Pharmacology, L N Medical College and research Center Bhopal, Madhya Pradesh from March 2017 to February 2018. Data analysis was done using SPSS ver 20 software. During this study 47% were prescribed metformin, 59% orlistat and 5% both drugs. Orlistat was largely prescribed independently [40 out of 50 prescriptions, 90%) and metforminon specialist recommendation (10 out of 40, 27%). Orlistat was largely prescribed in those over 16 years of age without physical comorbidities. Metformin was initiated for treatment of polycystic ovarian syndrome (70%), insulin resistance (25%) and impaired glucose-control (9%). Orlistat was the most common AOD prescribed in obese patients.